Treatment exposure
PD
As of December 6, 2017, all 59 patients ceased study therapy, most of them due to PD. Furthermore, 61.3% (19/31) of patients in the CIK-SOX group and 53.5% (15/28) of patients in the SOX group received follow-up chemotherapy, while 12.9% (4/31) and 7.1% (2/28) of patients, respectively, received radical gastrectomy.